Willkommen bei Scribd!

NUCYRETA ® (Tapentadol) Extended-Release Oral Tablets

Hochgeladen von

0% fanden dieses Dokument nützlich (0 Abstimmungen)

35 Ansichten1 Seite

NUCYRETA ® (tapentadol) extended-release oral tablets NUCYRETA® ER (tapentadol) extended-release oral tablets C-II NUCYRETA® is an opioid analgesic indicated for the management of moderate to severe acute pain in adults. Tapentadol is an opioid pain medication. An opioid is sometimes called a narcotic. Tapentadol is used to treat moderate to severe pain. The extended-release form of this medicine (Nucynta ER) is for around-the-clock treatment of pain that is not controlled by other medicines. Tapentadol (brand names: Nucynta, Palexia and Tapal) is a centrally acting opioid analgesic of the benzenoid class with a dual mode of action as an agonist of the μ-opioid receptor and as a norepinephrine reuptake inhibitor (NRI).[1] Analgesia occurs within 32 minutes of oral administration, and lasts for 4–6 hours.[3] It is similar to tramadol in its dual mechanism of action; namely, its ability to activate the mu opioid receptor and inhibit the reuptake of norepinephrine.[3] Unlike tramadol, it has only weak effects on the reuptake of serotonin and is a significantly more potent opioid with no known active metabolites.[3][4] Tapentadol is not a pro-drug and therefore does not rely on metabolism to produce its therapeutic effects; this makes it a useful moderate-potency analgesic option for patients who do not respond adequately to more commonly used opioids due to genetic disposition (poor metabolizers of CYP3A4 and CYP2D6), as well as providing a more consistent dosage-response range among the patient population. Tapentadol general potency is somewhere between that of tramadol and morphine,[5] with an analgesic efficacy comparable to that of oxycodone despite a lower incidence of side effects.[1] It is generally regarded as a weak-moderate strength opioid. Tapentadol was approved by the US FDA in November, 2008,[6] by the TGA of Australia in December 2010[7] and by the MHRA of the UK in February 2011.1[8] tapentadol vs oxycodone tapentadol high tapentadol vs tramadol tapentadol side effects tapentadol dose tapentadol 50 mg tapentadol 100 mg tapentadol hydrochloride taj pharma contact, taj pharmaceuticals api list, taj pharmaceuticals manufacturing unit taj pharmaceuticals ltd valsad, taj pharma product list taj pharmaceuticals careers, taj pharmaceuticals contact details, taj pharmaceuticals stock taj pharma contact, taj pharmaceuticals api list taj pharmaceuticals ltd valsad, taj pharmaceuticals manufacturing unit taj pharma product list, taj pharmaceuticals careers taj pharmaceuticals contact details ,taj pharmaceuticals stock taj pharmaceuticals turnover, shantanu kumar singh taj pharma, taj pharmaceuticals limited ahmedabad Mr.Abhishek Singh (ceo Taj pharma),, taj pharmaceuticals pvt ltd taj pharmaceuticals ltd valsad , taj pharmaceuticals manufacturing unit taj pharma contact, taj pharmaceuticals turnover taj pharma product list , taj pharmaceuticals api list taj pharmaceuticals products, taj pharma contact taj pharmaceuticals products, taj pharmaceuticals ltd valsad taj pharmaceuticals turnover, taj pharmaceuticals api list taj pharmaceuticals manufacturing unit, taj pharma product list taj pharmaceuticals limited ahmedabad, priyanka singh taj pharma taj pharmaceuticals turnover, abhishek kumar singh taj pharma

Originaltitel

NUCYRETA ® (tapentadol) extended-release oral tablets

Copyright

Verfügbare Formate

PDF, TXT oder online auf Scribd lesen

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Dieses Dokument melden

Copyright:

Verfügbare Formate

Als PDF, TXT herunterladen oder online auf Scribd lesen

Markieren Sie unangemessene Inhalte

0% fanden dieses Dokument nützlich (0 Abstimmungen)

35 Ansichten1 Seite

NUCYRETA ® (Tapentadol) Extended-Release Oral Tablets

Hochgeladen von

Anonymous BVD7IKf

Copyright:

Verfügbare Formate

Als PDF, TXT herunterladen oder online auf Scribd lesen

Markieren Sie unangemessene Inhalte

Zu Seite

Sie sind auf Seite 1von 1

Im Dokument suchen

NUCYRETA CII

NEW

tapentadol extended-release tablets